SAR and mode of action of novel non-nucleoside inhibitors of hepatitis CNS5b RNA polymerase

被引:123
作者
Powers, JP [1 ]
Piper, DE
Li, Y
Mayorga, V
Anzola, J
Chen, JM
Jaen, JC
Lee, G
Liu, JQ
Peterson, MG
Tonn, GR
Ye, QP
Walker, NPC
Wang, ZL
机构
[1] Amgen Inc, Dept Chem, Mail Stop ASF2-327,1120 Vet Blvd, San Francisco, CA 94080 USA
[2] Amgen Inc, Dept Biol Struct, San Francisco, CA 94080 USA
[3] Amgen Inc, Dept Biol, San Francisco, CA 94080 USA
[4] Amgen Inc, Dept Pharmacokinet & Drug Metab, San Francisco, CA 94080 USA
关键词
D O I
10.1021/jm050859x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Novel non-nucleoside inhibitors of the HCV RNA polymerase (NS5b) with sub-micromolar biochemical potency have been identified which are selective for the inhibition of HCV NS5b over other polymerases. The structures of the complexes formed between several of these inhibitors and HCV NS5b were determined by X-ray crystallography, and the inhibitors were found to bind in an allosteric binding site separate from the active site. Structure-activity relationships and structural studies have identified the mechanism of action for compounds in this series, several of which possess drug-like properties, as unique, reversible, covalent inhibitors of HCV NS5b.
引用
收藏
页码:1034 / 1046
页数:13
相关论文
共 64 条
[21]   Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase [J].
Dhanak, D ;
Duffy, KJ ;
Johnston, VK ;
Lin-Goerke, J ;
Darey, M ;
Shaw, AN ;
Gu, BH ;
Silverman, C ;
Gates, AT ;
Nonnemacher, MR ;
Earnshaw, DL ;
Casper, DJ ;
Kaura, A ;
Baker, A ;
Greenwood, C ;
Gutshall, LL ;
Maley, D ;
DelVecchio, A ;
Macarron, R ;
Hofmann, GA ;
Alnoah, Z ;
Cheng, HY ;
Chan, G ;
Khandekar, S ;
Keenan, RM ;
Sarisky, RT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (41) :38322-38327
[22]   Hepatitis C and hepatocellular carcinoma [J].
DiBisceglie, AM .
HEPATOLOGY, 1997, 26 (03) :S34-S38
[23]   Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution [J].
Ding, JP ;
Das, K ;
Hsiou, Y ;
Sarafianos, SG ;
Clark, AD ;
Jacobo-Molina, A ;
Tantillo, C ;
Hughes, SH ;
Arnold, E .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 284 (04) :1095-1111
[24]  
El-Bindary AA, 1998, MONATSH CHEM, V129, P1259, DOI 10.1007/PL00010137
[25]  
GARDELLI C, 2002, Patent No. 0206246
[26]   Control of hepatitis C: A medicinal chemistry perspective [J].
Gordon, CP ;
Keller, PA .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (01) :1-20
[27]   SYNTHESIS OF 3-AMINORHODANINE DERIVATIVES AS ALDOSE REDUCTASE INHIBITORS [J].
HANEFELD, W ;
SCHLITZER, M .
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1995, 32 (03) :1019-1025
[28]   Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase [J].
Harper, S ;
Pacini, B ;
Avolio, S ;
Di Filippo, M ;
Migliaccio, G ;
Laufer, R ;
De Francesco, R ;
Rowley, M ;
Narjes, F .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) :1314-1317
[29]  
HASHIMOTO H, 2001, Patent No. 0147883
[30]   Hepatitis C: The clinical spectrum of disease [J].
Hoofnagle, JH .
HEPATOLOGY, 1997, 26 (03) :S15-S20